

Transparency Guidelines on Relation with Medical Institutions

February 1, 2020
TAUNS Laboratories, Inc.

Basic Policy

TAUNS Laboratories, Inc. (hereinafter “the Company”) establishes “Transparency Guidelines on Relation with Medical Institutions”, referring to the “Transparency Guidelines for the Relation between Corporate Activities and Medical Institutions” of the Japan Association of Clinical Reagents Industries, and defined it as our code of practice. The purpose of this Guidelines is to gain a wide understanding that our corporate activities contribute to the development of life sciences including medical care, and are conducted with high ethical standards.

Disclosure of Funding Provided to Medical Institutions

1. Method of Disclosure

The information is disclosed at the website of TAUNS Laboratories, Inc.
(<https://www.tauns.co.jp>)

2. Timing of Disclosure

Information is disclosed after the release of the financial statements for the previous fiscal year for one year.

3. Scope of Disclosure

The scope of information to be disclosed with regard to funding to medical institutions is as follows:

A) Research and Development Expenses

Research and development expenses here includes expenses associated with clinical studies, clinical trials, adverse drug reactions/infection case reporting conducted under public regulations such as the Good Vigilance Practice (GVP) ordinances, and post-marketing surveillance activities.

Joint research expenses	Name of the relevant institution ^(*1) , Annual number of cases/total amount
Research commissioning expenses	Name of the relevant institution ^(*1) , Annual number of cases/total amount
Other expenses related to research and development	Annual total amount

(*1) Name of the relevant institution: “Name of the institution”, “Name of the organization within the institution”, or “Affiliation/title/name of an individual” shall be published based on the contents of the contract.

B) Academic Research Support Expenses

Scholarship donations and general donations for promotion of academic research or research support, etc., donations to academic societies, etc. for supporting conferences, and expenses for co-sponsored conferences with academic societies, etc.

Scholarship donation	XX Department of XX University: Number of donations, XX yen
General donation	XX University (XX Foundation): Number of donations, XX yen
Donation to academic society, etc.	XXth XX Academic Society Meeting (XX Regional Meeting, XX Study Group Meeting): XX yen
Expenses of co-sponsored conference, etc.	XXth XX Academic Society Meeting, XX Seminar: XX yen

C) Manuscript/Writing Fees, etc.

Fees for lectures and writing or supervision of the manuscript for provision of scientific information, etc. on the company's pharmaceutical products, medicine, and pharmacy or fees that are related to research and development, and fees paid for commissioning of operations including consulting contracts, etc.

Lecture fees	Professor (Director) XX, XX Department of XX University (XX Hospital): Number of services, XX yen
Manuscript writing fee/supervision fees	Professor (Director) XX, XX Department of XX University (XX Hospital): Number of services, XX yen
Consulting, etc. commissioning fees	Professor (Director) XX, XX Department of XX University (XX Hospital): Number of services, XX yen

D) Information Provision Related Expenses

Expenses of lecture meetings and explanation meetings for providing information, etc. related to the company's pharmaceutical products, medicine and pharmacy to healthcare professionals

Expenses for meetings including lectures, etc.	Annual number of meetings and total amount
Explanation meeting expenses	Annual number of meetings and total amount
Medical/pharmaceutical literature, etc. supply expenses	Annual total amount

E) Other Expenses

Expenses for hospitality, etc. as social courtesy

Expenses for hospitality, etc.	Annual total amount
--------------------------------	---------------------